H. Lundbeck A/s

Other

H. Lunbeck A/s

Benny Bang-Andersen

Heidi Lopez De Diego

Kim Andersen

Ask Puschl

Thomas Ruhland

Garrick Paul Smith

Jan Kehler

Ejner Knud Moltzen

Andre Faldt

Tine Bryan Stensbol

Jakob Felding

Rene Holm

Allan Carsten Dahl

Mark Howells

Henrik Svane

Arne Mork

Jens Kristian Perregaard

Henrik Pedersen

Robert Dancer

Morten Jorgensen

Ole Nielsen

Ivan Mikkelsen

Lars Ole Lyngso

Connie Sanchez Morillo

Lone Munch Ringgard

Karina Krøjer Søby

Klaus Gjervig Jensen

Gitte Kobberoee Mikkelsen

Mogens Larsen

Sherry Collier

Silke Miller

Michael Harold Rock

Martin Juhl

Anette Graven Sams

Ask Püschl

Morten Jørgensen

Klaus P Bogeso

Povl Krogsgaard-Larsen

Nicholas Moore

Erhad Ascic

Klaus Peter B&oslash;ges&oslash;

Sibylle Moltzen Lenz

Michael J Mealy

André Faldt

Krestian Larsen

Niels Mørk

Klaus Peter Bøgesø

Jennifer Larsen

Ask Pueschl

Lone Munch Ringgaard

Lars Torup

Jorgen Brodersen

Lars Ole Lyngsø

Niels Mork

René Holm

Annette Graven Sams

Tomas Mow

Håkan Wikström

Ask PÜSCHL

Arne MØRK

Tine Bryan STENSBØL

Morten JØRGENSEN

Jørgen Brodersen

HåKan Wikström

Niels Moerk

Morten Joergensen

The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.

Catecholamine prodrugs for use in the treatment of Parkinson's disease

The invention provides compounds represented by the general formula I wherein the substituents are defined in the application. The compounds are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.

Phenyl-piperazine derivatives as serotonin reuptake inhibitors

A dose regimes comprising the simultaneous administration of two pharmaceutical compositions, wherein the first pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof for once daily oral administration, and the second pharmaceutical composition is a composition comprising vortioxetine or a pharmaceutically acceptable salt thereof which together with said first composition quickly achieves a steady-state plasma level of vortioxetine in said patient which steady-state plasma level is the same as the steady-state vortioxetine plasma level achieved by the administration to said patient of said first composition alone.

Dosing regimens for fast onset of antidepressant effect

Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine and salts thereof are provided, e.g., for the treatment of neuropathic pain.

Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine

This disclosure relates to 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof in a crystalline form.

[object Object]

This disclosure relates to a method of treating a disease selected from the group consisting of Alzheimer's disease, cognitive impairment, and attention deficit hyperactivity disorder (ADHD). The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.

1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HTand 5-HTand may as such be useful for the treatment of cognitive impairment, especially in depressed patients. 

This disclosure relates to a method of treating a disease selected from the group consisting of affective disorders, depression, major depressive disorder, anxiety, general anxiety disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, and panic attacks. The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to a patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.

1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment

1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment

The present invention relates to radiolabelled PDE10A ligands which are useful for imaging and quantifying the PDE10A enzyme using positron emission tomography (PET).

Radiolabelled phenylimidazole-based ligands

Growing community of inventors

Copenhagen, Denmark

Benny Bang-Andersen